| Chemical Properties | Back Directory | [Boiling point ]
670.3±55.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [solubility ]
DMSO: Soluble
Methanol: Soluble | [form ]
Solid | [pka]
14.46±0.46(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
OT-82 is a potent NAMPT Inhibitor that targets the strong dependence of hematological malignancies on NAD biosynthesis. OT-82 showed strong efficacy against hematopoietic malignancies including acute myeloblastic and lymphoblastic adult and pediatric leukemias, erythroleukemia, multiple myeloma, and Burkitt's lymphoma in vitro and in mouse xenograft models. | [Uses]
OT-82 is a potent, selective and orally active inhibitor of NAMPT. OT-82 is selectively toxic to cells of hematopoietic origin and?induces cell death in a NAD+ dependent manner. OT-82 is a promising antineoplastic agent for the study of hematological malignancies[1]. | [in vivo]
OT-82 (oral gavage; 20 or 40 mg/kg; 3 weeks) treatment increases survival to 100% and 56% at 40 or 20 mg/kg, respectively after treatment discontinuation in SC xenograft model of Burkitt's lymphoma[1]. | Animal Model: | SC xenograft model of Burkitt's lymphoma in SCID mice[1] | | Dosage: | 20 or 40 mg/kg | | Administration: | oral gavage; 3 weeks | | Result: | Potently inhibited tumor growth of multiple myeloma mouse model. |
| [References]
[1] Korotchkina L, et al. OT-82, a?novel?anticancer?drug?candidate?that?targets?the?strong?dependence?of?hematological?malignancies?on?NAD?biosynthesis.Leukemia.?2020 Jan 2. DOI:10.1038/s41375-019-0692-5 |
|
|